The Crk SH2/SH3 adaptor and the Abl nonreceptor tyrosine kinase were first identified as oncoproteins, and both can induce tumorigenesis when overexpressed or mutationally activated. We previously reported the surprising finding that inhibition or knockdown of Abl family kinases enhanced transformation of mouse fibroblasts by CrkI. Abl family inhibitors are currently used or are being tested for treatment of human malignancies, and our finding raised concerns that such inhibitors might actually promote the growth of tumors overexpressing CrkI. Here, we identify the Dok1 adaptor as the key effector for the enhancement of CrkI transformation by Abl inhibition. We show that phosphorylation of tyrosines 295 and 361 of Dok1 by Abl family kinases suppresses CrkI transforming activity, and that upon phosphorylation these tyrosines bind the SH2 domains of the Ras inhibitor p120 RasGAP. Knockdown of RasGAP resulted in a similar enhancement of CrkI transformation, consistent with a critical role for Ras activity. Imaging studies using a FRET sensor of Ras activation revealed alterations in the localization of activated Ras in CrkI-transformed cells. Our results support a model in which Dok1 phosphorylation normally suppresses localized Ras pathway activity in Crk-transformed cells via recruitment and/or activation of RasGAP, and that preventing this negative feedback mechanism by inhibiting Abl family kinases leads to enhanced transformation by Crk.
INTRODUCTION
Crk was first identified as the oncogene of avian sarcoma virus CT10. 1 Later studies identified the cellular homologs of the viral oncoprotein (v-Crk): CrkI and CrkII are alternatively spliced forms of Crk, 2 and CRKL is encoded by a different gene but is highly similar to CrkII in sequence and overall structure. 3 Crk was the first example of an SH2/SH3 adaptor, a family of small proteins that lack catalytic domains but contain multiple modular proteinbinding domains. CrkI and v-Crk consist of one SH2 and one SH3 domain, whereas CrkII and CRKL both have an additional C-terminal SH3 domain. 2, 4 CrkII also contains a regulatory tyrosine residue (Y221 in human CrkII) 4 that, when phosphorylated by Abl family kinases, binds intramolecularly to the SH2 domain and thus downregulates biological activity. 5 This negative regulatory site is not present in CrkI and v-Crk. Crk overexpression has been reported in several types of human cancer, [6] [7] [8] and also in established cancer cell lines. 9, 10 Expression levels of Crk correlated with the aggressiveness of tumor cells, consistent with a positive role in cancer. In the laboratory, CrkI overexpression has been used as a model to study the transforming mechanisms of Crk. 2, 11 Like other adaptors, Crk proteins function in signaling by mediating the formation of multiprotein complexes through their modular protein-binding domains, 12 and transformation by v-Crk and CrkI requires the binding activity of both the SH2 and SH3 domains. 11, 13 The Crk SH2 domain binds tyrosine-phosphorylated peptides with pY-x-x-P motifs, 14 and its major binding partners include the focal adhesion proteins paxillin 15 and p130Cas. 16 The N-terminal SH3 domain of Crk binds proline-rich peptides with P-x-x-P-x-K motifs, 17, 18 and the major binding partners include Abl family tyrosine kinases, 19, 20 and small G protein guanine nucleotide exchange factors including Sos, 21 DOCK180 22 and C3G. 18 In our previous work to identify the Crk SH3 binding partners essential for transformation of NIH3T3 cells by CrkI, we found that the activity of Abl family kinases antagonized the transforming activity of Crk. 11 Knocking down expression of Abl and its close relative Arg, or inhibiting Abl family kinases with imatinib (a clinically prescribed Abl kinase inhibitor), both led to increased tumorigenicity of CrkI overexpressing cells in vitro (assayed by anchorage-independent growth) and in vivo (assayed by injection of cells into nude mice).
The Abl tyrosine kinase, originally identified in Abelson murine leukemia virus, 23 causes chronic myelogenous leukemia in humans through a chromosomal translocation resulting in a fusion protein, Bcr-Abl, with constitutively high kinase activity. 24 Clinically, imatinib and similar compounds work by inhibiting Abl kinase activity and are effective in treating chronic myelogenous leukemia. Imatinib has also been shown to inhibit platelet derived growth factor receptor 25, 26 and c-Kit. 27 Due to the efficacy of imatinib in chronic myelogenous leukemia treatment, it and other Abl inhibitors are now used to target Abl, platelet derived growth factor receptor and c-Kit in various types of cancer. [28] [29] [30] However, our recent observations raise concerns that Abl inhibitors have the potential to promote the growth and survival of tumor cells in some instances, particularly in those with CrkI overexpression. We therefore sought to understand the mechanism whereby Abl inhibition promotes transformation by Crk.
In this study, we show that Dok1 is responsible for the enhancement of CrkI transformation upon Abl kinase inhibition. Dok1 was first discovered as a substrate for Abl, 31, 32 and is one of seven members to the Dok family. 33 Dok family proteins lack catalytic domains, consisting of a Pleckstrin Homology (PH) domain, a phosphotyrosine (pTyr) binding (PTB) domain, and a C-terminal tail with multiple tyrosine residues that can be phosphorylated and thereby recruit pTyr binding proteins.
33
Dok1 and Dok2 negatively regulate B-cell receptor (BCR) 34 and T-cell receptor (TCR) 35 signaling and modulate the proliferation of myeloid cells. 36, 37 Dok1, 2 and 3 also have been shown to possess tumor suppressor activity in several studies. 38, 39 Our results suggest the existence of a general feedback control mechanism whereby Abl, Dok family proteins and RasGAP work together to locally downregulate Ras activity.
RESULTS

Dok1 is the major Abl-dependent phosphoprotein in
Crk-transformed cells We first examined more closely how Abl inhibition affected the ability of CrkI-transformed NIH3T3 cells to grow in suspension, a hallmark of malignant transformation. Consistent with previous results, 11 we found a significant increase (up to 10-fold) in the number of colonies in the soft agar growth assay when cells were treated with the Abl inhibitor imatinib (Figure 1a ). The stimulatory effect of imatinib increased proportionately with concentration up to 10 μM then decreased slightly, presumably due to increased toxicity (the reported IC 50 for imatinib falls within the range of 0.4-1.5 μM 40 ). We reasoned that Abl inhibition exerted its effects on Crk transformation by altering tyrosine phosphorylation. To identify Abl-dependent phosphoproteins, lysates of control and CrkItransformed cells (with and without imatinib treatment) were immunoblotted with anti-phosphotyrosine (anti-pTyr) antibody. A prominent tyrosine-phosphorylated band of~64 kDa was seen in CrkI overexpressing cells when compared with the controls, the phosphorylation of which was strongly reduced upon imatinib treatment (Figure 1b) . On the basis of known substrates of Abl and the apparent molecular weight, we surmised that this phosphoprotein might be Dok1. 31 To test this, a lysate of Crk-transformed cells was serially immunoprecipitated with anti-Dok1 antibody. This treatment depleted the 64 kDa tyrosine-phosphorylated protein from the lysates, verifying its identity as Dok1 (Figure 1c ). Immunoblotting with a phosphospecific antibody recognizing pY362 of human Dok1 (pY361 in mouse Dok1) further confirmed the dependence of Dok1 phosphorylation on Abl activity (Figure 1d) . Dok1 corresponded to the only prominent tyrosinephosphorylated band in CrkI-transformed cells that was Abldependent. Somewhat paradoxically, Dok1 phosphorylation was increased in CrkI-transformed cells compared with normal control cells (Figure 1b) . Together, these data suggest that tyrosine phosphorylation of Dok1 by Abl is induced by CrkI overexpression, and may act to partially suppress Crk-mediated transformation.
Phosphorylation of Dok1 regulates CrkI transformation
To test whether Dok1 is acting as a tumor suppressor protein in this system, we knocked down Dok1 expression in CrkI overexpressing cells using shRNA (Figure 2b ). We observed an enhancement of soft agar colony formation upon Dok1 knockdown, comparable to the effect of Abl knockdown or imatinib treatment (Figure 2c) , implicating Dok1 as a crucial regulator of CrkI transformation. To further probe the significance of Dok1 in suppressing CrkImediated transformation, the human homolog of Dok1 (hDok1) was used for rescue experiments. We used human instead of mouse Dok1 to avoid it being targeted for shRNA-mediated knockdown. The human homolog of Dok1 has an insertion at position 271, which shifts the amino acid numbering C-terminal to the insertion by +1 compared with mouse. For simplicity, henceforth the mouse amino acid numbering will be used unless stated otherwise.
In addition to the wild-type (WT) hDok1, we also generated mutant constructs to test the importance of several potential tyrosine phosphorylation sites. Shinohara et al. 41 reported that phosphorylation of tyrosines 259 and 361 was required for RasGAP binding, whereas phosphorylation of tyrosines 336 and 340 inhibited Erk activation through unidentified mechanism(s). Both Ras and its activator Sos1 were previously shown to have essential roles in Crk transformation, 11, 42 and the MEK/ERK pathway downstream of Ras is well known to promote cell proliferation. 43 Using site-directed mutagenesis, putative tyrosine phosphorylation sites were changed to phenylalanine. The resulting constructs were named according to the tyrosines mutated ( Figure 2a ): M14 for mutation of sites 1 and 4 (Y295 and Y361), M23 for mutation of sites 2 and 3 (Y336 and Y340), M-all for mutation of all four sites, M1 for mutation of Y295 and M4 for mutation of Y361. These constructs were re-expressed in the CrkI- greater increase in colony formation than seen with Dok1 knockdown alone. Expression of single mutants (M1 and M4) partially rescued the Dok1 knockdown phenotype. These results suggested that Y295 and Y361 work together to suppress CrkI tumorigenesis when phosphorylated. Dok1 knockdown followed by re-expression of WT or mutant Dok1 in control NIH3T3 cells yielded no colonies (data not shown), consistent with the effect of Dok1 tumor suppression being specific to cells transformed by Crk.
We also tested the effect of simple Dok1 overexpression in CrkItransformed NIH3T3 cells (Figure 2d ). Consistent with its role as a putative tumor suppressor, overexpression of WT Dok1 and the M23 Dok1 mutant both suppressed CrkI transformation in the soft agar assay; by contrast, the M14 and M-all mutants enhanced CrkI transformation ( Figure 2e ). This demonstrates that expression of Dok1 mutants that cannot be phosphorylated at sites 295 and 361 exerts a dominant-negative (pro-oncogenic) effect over endogenous Dok1. Surprisingly, overexpression of the M1 and M4 single mutants showed a greater suppression of transformation than seen for WT Dok1. Once again, these results were CrkI-dependent, as no colonies were seen in control 3T3 cells overexpressing Dok1 mutants (data not shown).
SH2 domain binding partners of tyrosine-phosphorylated Dok1
Most tyrosine-phosphorylated sites function in signaling by binding to the SH2 or PTB domains of effector proteins. 44 To assess what SH2 domains bind to the Dok1 sites implicated in suppressing CrkI transformation, we carried out a dot-blot SH2 profiling assay 45 using purified glutathione S-transferase (GST)-SH2 or GST-PTB domain fusion proteins to probe synthetic tyrosine-phosphorylated peptides corresponding to the four sites of interest in Dok1 (Figure 3a) .
Of the 123 SH2 or PTB probes tested (Supplementary Figure S1 ), a few showed strong binding to Dok1-derived phosphopeptides. Abl and Arg (Abl2) SH2 domains strongly bound to all four phosphorylated sites, but not the unphosphorylated control peptides ( Figure 3c ). As expected, the SH2 domains of RasGAP bound strongly to pTyr 295 and 361. The C-terminal RasGAP SH2 domain bound specifically to pTyr 295, whereas the N-terminal domain was less specific and bound to phosphopeptides corresponding to tyrosines 295, 340 and 361. SH2 domains of p85α, a subunit of phosphatidylinositol 3-kinase, also bound to phosphorylated sites in Dok1. The N-terminal SH2 domain of p85α bound pTyr 336, whereas a construct encompassing both SH2 domains bound pTyr 295, 336 and 361. Notably, none of the phosphopeptides tested bound strongly to the Crk SH2 domain (Figure 3c ). The unphosphorylated peptides did not bind appreciably to any of the SH2 domain probes, highlighting the specificity of our SH2 probes for tyrosine-phosphorylated peptides.
We also performed far-western blotting to probe imatinibtreated cell lysates with RasGAP SH2 domains. The RasGAP SH2 probes bound to a band in Crk-transformed cells corresponding to phosphorylated Dok1; binding was abolished when Abl-mediated phosphorylation was inhibited with imatinib ( Figure 3d ). The relatively less specific RasGAP N-terminal SH2 domain showed the strongest difference in binding to Dok1 when cells were treated with imatinib. This suggests that in vivo, Abl preferentially phosphorylates site 4 (Y361) relative to site 1 (Y295), as little binding was seen with the RasGAP C-terminal SH2 probe, which is highly specific to site 1. A similar pattern of binding was also observed in the control 3T3 cell lysates, albeit at a much lower intensity.
Role of RasGAP in regulating Crk transformation
We next sought to confirm that RasGAP binds to phosphorylated Dok1 in our cell system by expressing HA-tagged hDok1 and immunoprecipitating with anti-HA antibody. To maximize the detection of phosphotyrosine-dependent interactions, cells were treated briefly with pervanadate (POV) before lysis to inhibit endogenous tyrosine phosphatases. Immunoblotting of anti-HA immunoprecipitates with anti-RasGAP antibody demonstrated association between RasGAP and WT Dok1; this binding was decreased, however, when tyrosines 295 and 361 were mutated (mutants M14 and M-all; Figure 4a ). These results are consistent with the results of phosphopeptide binding experiments (Figure 3) . The M1 and M4 mutants of Dok1 both associated with RasGAP to a similar extent as WT Dok1, demonstrating that, under these conditions, phosphorylation of either Y295 or Y361 alone is sufficient to mediate RasGAP binding.
Next we knocked down RasGAP in both the control and CrkI overexpressing cells (Figure 4b) . Loss of endogenous RasGAP in CrkI-transformed NIH3T3 increased the number of colonies (Figure 4c Figure S2 ). We therefore considered whether CrkI overexpression might induce localized differences in Ras activity that were not evident in total cell lysates. To study the spatiotemporal aspects of Ras activation, we employed a newly developed FRET sensor for activated Ras (dimerization optimized reporter for activation (Dora)-Ras) and conducted live cell imaging of Ras activation during cell spreading on fibronectin. As Ras is activated on the plasma membrane, we used total internal reflection fluorescence (TIRF) excitation in our imaging studies to reduce imaging artifacts typically associated with wide-field imaging. Fifteen minutes after plating, cells transiently transfected with Dora-Ras sensor showed elevated ratio (FRET/CFP) values, indicative of Ras activation, in lamellipodial protrusions (Figure 5a ). In contrast, cells transfected with a control construct (with a point mutation in the Ras binding domain that abolishes sensor response), showed no polarized distribution of ratio values (Figure 5b) .
Crk is known to localize to adhesions by binding to phosphorylated paxillin and p130Cas, [46] [47] [48] [49] and we showed that CrkI was enriched at paxillin-containing adhesions in CrkI overexpressing cells (Supplementary Movie S3). To relate sites of Ras activation to the location of adhesions, we co-expressed mCherry-tagged paxillin with the Dora-Ras sensor. In control NIH3T3 cells, Ras activity colocalized with nascent adhesions at the leading front, but diminished in the vicinity of mature focal adhesions as the cells spread (Figure 5c and Supplementary Movie S4). In contrast, CrkI-transformed cells maintained elevated Ras activation while adhesions matured (Figure 5d and Supplementary Movie S5). Strikingly, the spatial distribution of Ras activation often appeared bipolar or multipolar, and the cells developed multiple protrusions at an early stage of cell spreading. Thus we conclude that the localized distribution of activated Ras is dramatically different in CrkI-transformed cells compared with their normal controls.
DISCUSSION
Unregulated Abl activity causes chronic myelogenous leukemia and other malignancies in humans, and small molecule Abl inhibitors are now widely used to treat cancer. In this context, our previous finding that Abl downregulation enhanced RasGAP knockdown increases the number of colonies in CrkI-transformed cells but has no effect on the empty vector control cells. transformation by Crk 11 was both surprising and potentially disturbing, as it raised the possibility that Abl inhibitors could promote instead of inhibit tumor growth in some situations. In fact, such a tumor-promoting effect of Abl inhibition had been reported in several previous studies, where Abl family kinases acted downstream of epithelial growth factor, 49 transforming growth factor-β 50 or EphrinB. 51 In each case, enhanced xenograft growth was reported upon downregulation of active Abl and/or Arg. Our current results add to our understanding of the complex mechanisms whereby Abl family kinases can both positively and negatively impact different aspects of cell transformation.
We have now identified Dok1 as the downstream effector responsible for enhancing CrkI transformation upon Abl inhibition. Dok1, Dok2 and Dok3 knockout mice were shown in two independent studies to develop lung tumors 38 and histiocytic sarcomas, 39 and the Dok1 gene maps to human chromosome 2p13, a frequent site of translocations in leukemia. 52 Frameshift mutation 53 and aberrant DNA methylation in the promoter region 54, 55 were reported for Dok1 in various human cancers. Taken together, these results are consistent with our current observation that Dok1 has an important role in downregulating CrkI-induced cell transformation.
In Figure 6 , we propose a model for how Abl regulates transformation through Dok1 phosphorylation. The overexpression of CrkI leads to its recruitment and clustering at membrane sites rich in tyrosine-phosphorylated proteins, such as focal adhesions. Crk in turn recruits its SH3 binding effectors such as Sos to these sites, leading to localized activation of Ras and ultimately resulting in cell transformation. At the same time, however, Crk triggers a negative feedback loop by recruiting Abl family kinases, which associate with and phosphorylate Dok1. Phosphorylated DokI recruits RasGAP, which counteracts the stimulation of Ras by Sos and thereby blunts Crk transformation. When Abl-mediated phosphorylation is inhibited (either by knockdown or imatinib), the resulting decrease in Dok1 phosphorylation prevents it from recruiting RasGAP, thereby increasing local Ras activation and enhancing transformation. Interestingly, we have noticed that CrkI overexpression reproducibly causes a modest increase in endogenous Dok1 expression in addition to increased Dok1 phosphorylation (see Figures 2b and d) , consistent with a negative feedback response to CrkI transformation.
While our data demonstrate a strong negative correlation between phosphorylated Dok1 and CrkI transformation, it is unclear what role this pathway has in other types of cell transformation. On one hand, we previously showed that imatinib had little effect on the anchorage-independent growth of cells transformed by Src or Ras, 11 and preliminary experiments with a panel of human cancer cell lines showed that Abl inhibitors do not generally stimulate the growth of tumor cells (KYN and BJM, unpublished observations). However, previous results showing that Dok proteins can negatively regulate signaling from the BCR and TCR, and that they exhibit tumor suppressor activity, suggest a more general role in feedback regulation of the Ras pathway. It is possible that the repressive role of Dok is particularly evident in Crk transformation because Crk is a relatively weak oncogene in mammalian fibroblasts.
Greulich and Hanafusa 42 previously showed that dominantnegative Ras mutants blocked transformation by v-Crk, and we later showed that Sos1, the major guanine nucleotide exchange factor for Ras, is by far the most critical SH3 binding protein of those tested for CrkI transformation. 11 However, the specific role of Ras activation in Crk transformation remains enigmatic, as we and others have not seen a consistent or significant increase in the activity of Ras or its downstream effectors in Crk-transformed cells relative to controls. 11, 42, 56 Our current results further implicate Ras activity in Crk transformation by demonstrating that phosphorylation of two sites in Dok1 that bind the Ras inhibitor RasGAP (tyrosines 295 and 361) is critical for suppressing Crk transformation. We show that Dok1 is highly phosphorylated in Crk-transformed cells, and that this phosphorylation is abrogated by the Abl inhibitor imatinib, which stimulates Crk transformation. We also show that overexpression of Dok1 mutants that cannot be phosphorylated at the RasGAP binding sites strongly stimulates Crk transformation, whereas expression of WT Dok1 or Dok1 mutants in which these sites are intact strongly inhibits anchorage-independent growth induced by CrkI overexpression. Finally, we also show that RasGAP knockdown enhances CrkI transformation (Figure 4c) .
Interestingly, Dok1 knockdown cells rescued with Dok1 mutated at tyrosines 295 and 361 (M14 and M-all) were even more transformed than the Dok1 knockdown alone (Figure 2) . A likely explanation is that the Dok1 mutants have a dominantnegative effect on the residual, endogenous Dok1 present in knockdown cells. The fact that simple overexpression of these Dok1 mutants had similar effects, even in the presence of unaltered endogenous Dok1, is also consistent with this idea. Phospho-dependent homotypic and heterotypic oligomerization between Dok1 and Dok2 is reported to be critical for their function, 57 so the presence of mutated Dok1 would likely disrupt the integrity of oligomers and compromise their normal ability to downregulate signaling.
One way to reconcile the apparent importance of Ras in Crk transformation with the lack of obvious elevation in total Ras activity in Crk-transformed cells is to suppose that Ras activation by CrkI is highly localized and therefore not apparent in whole cell lysates. Indeed, during cell spreading we noted striking differences in the localization of activated Ras in Crk-transformed cells relative to controls ( Figure 5 ). In general, upon spreading, control cells rapidly formed a single leading edge where Ras activity was highest, whereas mature focal adhesions with the highest concentration of paxillin and Crk were mostly found along the sides and trailing edge of the cell, away from the areas of highest Ras activity. Others have previously noted that activated Ras is enriched in lamellipodia and the leading edge of polarized cells. 58, 59 In CrkI-transformed cells, however, most cells formed multiple highly protrusive fronts with high Ras activity, which in some cases coincided with mature focal adhesions. This phenotype is consistent with the partial loss of a negative feedback loop that normally functions to repress Ras at focal adhesions after a brief burst of activity.
The predominant form of Crk in normal cells, CrkII, contains a C-terminal region with a negative regulatory Abl phosphorylation site. 60, 61 The highly related CRKL protein also contains a homologous tyrosine phosphorylation site. 62, 63 In normal cells, CrkII recruited to focal adhesions is likely to be rapidly downregulated by Abl, and thus can only transiently recruit effectors such as Sos to adhesions. CrkI, by contrast, lacks this negative regulatory site. Thus in cells overexpressing CrkI, one might expect relatively sustained Ras activation at sites where Crk is localized, such as focal adhesions. In these cells, however, Dok1 phosphorylation appears to trigger a slower, less efficient downregulatory mechanism for Ras via the recruitment of RasGAP. Inhibition or knockdown of Abl family kinases, Dok1 or RasGAP inhibits this second feedback loop, and likely exacerbates the mislocalization of Ras activation seen in CrkI overexpressing cells. Further experiments will be needed to tease out the effects of this local feedback inhibition on proliferative signaling, and on cell motility and polarity in general.
Our results suggest that CrkI overexpression has both positive and negative effects on cell transformation, through different sets of protein interactions. Inputs that interfere with some of these interactions will shift this equilibrium, pushing the cell toward one extreme or the other (normal vs tumorigenic). Consistent with this idea, Crk transformation of mammalian cells is relatively weak, presumably at least in part because of the negative feedback provided by phosphorylation of Dok1 by Abl. The ability of Crk to transform cells is likely to depend not only on the level of Crk overexpression, but also on the relative abundance of positive effectors such as Sos, versus potential negative regulators such as Abl, Dok1 and RasGAP. Our results highlight the importance of understanding the role of negative feedback loops when considering therapies that incorporate Abl inhibition for the treatment of human tumors. 
MATERIALS AND METHODS
Cell culture, transfection and viral infection NIH3T3 fibroblasts were maintained in Dulbecco's Modified Eagle's medium supplemented with 10% super calf serum (SCS) (Gemini Bioproducts, West Sacramento, CA, USA). Serum starvation was carried out by maintaining the cells in Dulbecco's Modified Eagle's medium with 0.1% serum overnight. Transient transfection was performed using Lipofectamine 2000 (Life Technologies, Grand Island, NY, USA) according to the manufacturer's instructions. Retrovirus stocks were produced and used to infect cells as described. 11 
DNA constructs
The CrkI MSCVpuro retroviral vector has been described.
11 Dok1 and its mutants were cloned into MSCVneo vector (Clontech, Mountain View, CA, USA). The tyrosine-to-phenylalanine Dok1 mutants were generated from WT cDNA 38 using standard site-directed PCR mutagenesis with Platinum Taq polymerase (Life Technologies). The GFP-and Cherry-paxillin constructs were generous gifts of Klaus Hahn (UNC-Chapel Hill).
Construction of Dora-Ras
The Dora-Ras sensor is based on established design principles. 58, 64 It contains an N-terminal Ras binding domain (Cys71-Ser161) derived from Byr2, followed by a fluorescent protein FRET pair (Cerulean3-Venus), and an intact, wild-type H-Ras at the C-terminus. To improve the dynamic range, structural optimization was used to couple the dimerization of fluorescent proteins with the interaction between Byr2 and activated H-Ras, 65 hence the name dimerization optimized reporter for activation (Dora). The detailed characterization of the sensor will be described elsewhere (manuscript in preparation). As a control, a point mutation (R83E) was introduced in the Ras binding domain to disrupt Ras binding. The mutant sensor controls for potential alterations of fluorescence in the cell that are independent of Ras activation.
Gene knockdown
The target sequences used for Abl/Arg, Dok1 and RasGAP knockdown were 5′-GAGTACTTGGAGAAGAAGA-3′,11 5′-GGTAATGTTCTCCTTTGAA-3′ (modified from Mihrshahi et al. 66 ) and 5′-AAGATGAAGCCACTACCCTATTT -3′ 67 respectively. The 68 bp and 72 bp DNA inserts were first hybridized then cloned into pSUPER-hygro retrovirus vector (Oligoengine, Seattle, WA, USA). Antibodies pTyr (P-Tyr-100) was from Cell Signaling (Danvers, MA, USA); Dok1 (A-3), pDok1 (Tyr362), Actin (I-19) and HA (Y-11) were from Santa Cruz Biotechnology (Dallas, TX, USA); CrkII (C-18) and Abl (8E9) were from BD Biosciences (San Jose, CA, USA); RasGAP (B4F8) was from Upstate Biotechnology (Lake Placid, NY, USA).
Anchorage-independent growth assay Cells were trypsinized, counted and suspended in 10% fetal bovine serum Iscove's Dulbecco's Modified Eagle's medium with 0.3% Bacto agar (BD Bioscience) on a base agar layer of the same medium with 0.6% agar. A total of 2.5 × 10 4 cells (Figure 1 ) or 5 × 10 4 cells (Figures 2 and 4) were seeded per 60 mm plate. Plates were fed with 1 ml of fresh medium every week. After 4 weeks, plates were stained with 0.005% crystal violet (SigmaAldrich, St Louis, MO, USA), photographed and colony numbers were calculated using ImageJ (NIH, Bethesda, MD, USA). For imatinib (LC Laboratories, Woburn, MA, USA) treatment, drug was present at the indicated concentration both in the initial plating medium and in the medium used for weekly feeding.
SH2-phosphopeptide binding assay and far-western blotting
Biotinylated synthetic peptides were synthesized in both phosphorylated and unphosphorylated forms (Genescript), carefully spotted onto a gelatincoated nitrocellulose membrane and fixed with 4% paraformaldehide for 5 min. The membrane was subjected to binding with a panel of GST-tagged pTyr binding domains as described. 45 Far-western blotting (Figure 3d ) was carried out as described previously 45 using HRPconjugated anti-GST antibody for detection.
Protein analysis
Cell lysis, immunoblotting and immunoprecipitation were performed as previously described. 11 For co-IP (Figure 4a ), cells were first treated with 200 μM pervanadate (POV) for 45 min before lysis. Equal amounts of lysate were precleared for 2 h with protein-A beads, then, supernatant was incubated with anti-HA and protein-A beads overnight. The next day, beads were washed 4 × with a high-salt KLB solution (500 mM NaCl) and once with standard KLB solution before addition of 5 × sample buffer.
Live cell imaging and sensor data processing Cells were seeded onto fibronectin (20 μg/ml) coated coverslips in phenol red-and vitamin-free Dulbecco's Modified Eagle's imaging medium (US Biological, Salem, MA, USA). Total internal refection fluorescence imaging was conducted on a customized Ti-E inverted microscope (Nikon, Tokyo, Japan) equipped with a multiline (440/515/594 nm) LMM5 laser merge module (Spectral Applied Research, Canada), a motorized XY stage (Ludl, Hawthorne, NY, USA), and a Stable Z-stage heater (Bioptechs, Butler, PA, USA). Images were acquired through a 60 × 1.49 NA total internal refection fluorescence objective (Nikon) on an iXon Ultra 897 EMCCD (Andor, Belfast, UK) under the control of MetaMorph software (Molecular Devices, Sunnyvale, CA, USA). Biosensor data were processed using custom routines written in MetaMorph and MATLAB (MathWorks, Natick, MA, USA) for background subtraction, image segmentation, channel registration and ratiometric arithmetic as described previously. 68 
